Table 2.
Significant miRNAs with potential prognostic and diagnostic biomarkers.
| Biomarker | Prognosis | Diagnosis | Tumor stages | Endpoint | Source | Ref. |
|---|---|---|---|---|---|---|
| miR-532-5p | Yes | No | Cell proliferation of ovarian neoplasms | OS | — | [242] |
| miR-200b | Yes | No | EMT and migration | OS | Ascitic fluid | [243, 244] |
| miR-193b | No | Yes | Lymph node metastasis | Poor survival | Tissue | [245] |
| miR-135a-3p | Yes | No | Cell proliferation of ovarian tumors | Decreased PFS | Peritoneal fluid | [246] |
| miR-125b | Yes | Yes | Lymph node involvement and distant metastasis | Decreased OS | Serum | [247] |
| miR-613 | Yes | No | Lymph node involvement | Short PFS and OS | Tissue | [248] |
| miR-506 | Yes | No | EMT | Decreased OS and PFS | Tissue | [249] |
| miR-205 | Yes | Yes | Advanced stages III/IV | — | Plasma | [250] |
| miR-200c-3p, miR-346, miR-127-3p | No | Yes | Distant metastasis | — | Serum | [251] |
| miR-200c | No | Yes | Stage I | OS and PFS | Tissue | [252] |
| miR-27a and miR-23a | Yes | No | Stages I-IV | OS, RFS, and short PFS (miR-27a) | Serum | [253] |
| miR-let-7 | Yes | No | Early tumor progression | Poor survival | Tissue | [241] |
| miR-221 | Yes | Yes | Stages I–IV | Decreased OS | Serum | [254] |
| miR-21 | Yes | Yes | Stages I–IV | OS | Serum | [255] |
| miR-335 | Yes | No | Distant metastasis (stages III/IV) | OS and RFS | Tissue | [256] |
| miR-429 | Yes | Yes | Stages III-IV | OS | Serum | [168] |
| miR-199a | Yes | Yes | Stages III-IV | Poor OS | [257] | |
| miR-1246 | No | Yes | Stages III-IV | — | Serum | [258] |
PFS: progression-free survival, OS: overall survival, RFS: recurrence-free survival.